Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer

1. Tolaney, S.
2. Burris, H.
3. Gartner, E.
4. Mayer, I.A.
5. Saura, C.
6. Maurer, M.
7. Ciruelos, E.
8. Garcia, A.A.
9. Campana, F.
10. Wu, B.
11. Xu, Y.
12. Jiang, J.
13. Winer, E.
14. Krop, I.